Literature DB >> 29192131

Amotosalen/UVA pathogen inactivation technology reduces platelet activability, induces apoptosis and accelerates clearance.

Beatrice Hechler1, Catherine Ravanat1, Christian Gachet2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 29192131      PMCID： PMC5709123          DOI： 10.3324/haematol.2017.180539

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

1.  Functional characteristics of photochemically treated platelets.

Authors:  Gerard A J Jansen; Huub H D M van Vliet; Hans Vermeij; Erik A M Beckers; Frank W G Leebeek; Pieter Sonneveld; Dick J van Rhenen
Journal:  Transfusion       Date:  2004-03       Impact factor: 3.157

2.  Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions.

Authors:  Miguel Lozano; Ana Galan; Roberto Mazzara; Laurence Corash; Ginés Escolar
Journal:  Transfusion       Date:  2007-04       Impact factor: 3.157

3.  Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation.

Authors:  Béatrice Hechler; Philippe Ohlmann; Philippe Chafey; Catherine Ravanat; Anita Eckly; Eric Maurer; Pierre Mangin; Hervé Isola; Jean-Pierre Cazenave; Christian Gachet
Journal:  Transfusion       Date:  2012-10-15       Impact factor: 3.157

4.  Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre.

Authors:  M Amato; H Schennach; M Astl; C Y Chen; J-S Lin; R J Benjamin; W Nussbaumer
Journal:  Vox Sang       Date:  2016-12-21       Impact factor: 2.144

5.  In response to the comment by Hechler et al.: Amotosalen/UVA pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance.

Authors:  Simona Stivala; Sara Gobbato; Laura Infanti; Martin F Reiner; Nicole Bonetti; Sara C Meyer; Giovanni G Camici; Thomas F Lüscher; Andreas Buser; Juerg H Beer
Journal:  Haematologica       Date:  2017-12       Impact factor: 9.941

6.  In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage.

Authors:  Torunn Ø Apelseth; Øystein Bruserud; Tore Wentzel-Larsen; Anne M Bakken; Solfrid Bjørsvik; Tor Hervig
Journal:  Transfusion       Date:  2007-04       Impact factor: 3.157

7.  Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period.

Authors:  Jean-Pierre Cazenave; Hervé Isola; Chantal Waller; Isabelle Mendel; Daniel Kientz; Michel Laforêt; Jean-Pierre Raidot; Gérard Kandel; Marie-Louise Wiesel; Laurence Corash
Journal:  Transfusion       Date:  2010-09-16       Impact factor: 3.157

8.  Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light.

Authors:  Edward Snyder; Thomas Raife; Lily Lin; George Cimino; Peyton Metzel; Margaret Rheinschmidt; Laurene Baril; Kathryn Davis; D H Buchholz; Laurence Corash; Maureen G Conlan
Journal:  Transfusion       Date:  2004-12       Impact factor: 3.157

9.  Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use.

Authors:  Jean Claude Osselaer; Chantal Doyen; Laurence Defoin; Cecile Debry; Maité Goffaux; Nathalie Messe; Maryse Van Hooydonk; Andre Bosly; Jin Sying Lin; Lily Lin; Laurence Corash
Journal:  Transfusion       Date:  2009-03-31       Impact factor: 3.157

10.  Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction.

Authors:  S M Picker; L Oustianskaia; V Schneider; B S Gathof
Journal:  Vox Sang       Date:  2009-03-18       Impact factor: 2.144
  10 in total
  3 in total

Review 1.  The Non-Hemostatic Aspects of Transfused Platelets.

Authors:  Caroline Sut; Sofiane Tariket; Cécile Aubron; Chaker Aloui; Hind Hamzeh-Cognasse; Philippe Berthelot; Sandrine Laradi; Andreas Greinacher; Olivier Garraud; Fabrice Cognasse
Journal:  Front Med (Lausanne)       Date:  2018-02-27

2.  Platelet Pathogen Reduction Technologies Alter the MicroRNA Profile of Platelet-Derived Microparticles.

Authors:  Idrissa Diallo; Abderrahim Benmoussa; Jonathan Laugier; Abdimajid Osman; Walter E Hitzler; Patrick Provost
Journal:  Front Cardiovasc Med       Date:  2020-03-19

3.  In Vitro Comparative Study of Platelets Treated with Two Pathogen-Inactivation Methods to Extend Shelf Life to 7 Days.

Authors:  Nicolas Malvaux; Fanette Defraigne; Styliani Bartziali; Camille Bellora; Kathleen Mommaerts; Fay Betsou; Anne Schuhmacher
Journal:  Pathogens       Date:  2022-03-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.